Table 2.
Patient and tumor characteristics
| Characteristics, N (%) | All patients | Therapeutic study type |
|||
|---|---|---|---|---|---|
| Genomically targeted | Immunotherapy | Other | No study | ||
| Sex | |||||
| Female | 1018 (53) | 179 (73) | 109 (52) | 221 (48) | 596 (51) |
| Male | 914 (47) | 66 (27) | 101 (48) | 235 (52) | 570 (49) |
| Sample typea | |||||
| Primary | 1003 (52) | 95 (39) | 89 (42) | 227 (50) | 645 (55) |
| Metastasis | 929 (48) | 150 (61) | 121 (58) | 229 (50) | 521 (45) |
| Sequencing platforma | |||||
| IMPACT 341 | 1297 (67) | 195 (80) | 146 (70) | 322 (71) | 745 (64) |
| IMPACT 410 | 635 (33) | 50 (21) | 64 (31) | 134 (29) | 421 (36) |
| Tumor type | |||||
| Genitourinary | 407 (21) | 15 (6) | 45 (21) | 117 (26) | 258 (22) |
| Breast | 393 (20) | 85 (35) | 23 (11) | 84 (18) | 254 (22) |
| Gynecologic | 221 (11) | 38 (15) | 34 (16) | 55 (12) | 117 (10) |
| Gastrointestinal | 143 (7) | 23 (9) | 13 (6) | 36 (8) | 89 (8) |
| Sarcoma | 134 (7) | 7 (3) | 12 (6) | 30 (7) | 82 (7) |
| Lung | 128 (7) | 21 (8) | 21 (10) | 14 (3) | 76 (7) |
| Head and neck | 101 (5) | 13 (5) | 29 (10) | 26 (6) | 48 (4) |
| Skin | 84 (4) | 14 (6) | 15 (7) | 5 (1) | 53 (5) |
| Thyroid | 83 (4) | 13 (5) | 0 (0) | 30 (7) | 41 (4) |
| Hepatobiliary | 82 (4) | 6 (3) | 1 (0) | 24 (5) | 52 (4) |
| Other | 156 (8) | 10 (4) | 31 (15) | 35 (8) | 97 (8) |
| Highest OncoKB levelb | |||||
| 1 | 115 (6) | 41 (17) | 15 (7) | 22 (5) | 52 (5) |
| 2 | 185 (10) | 53 (22) | 23 (11) | 44 (10) | 90 (8) |
| 3 | 410 (21) | 108 (44) | 38 (18) | 87 (19) | 231 (20) |
| Unranked | 1222 (63) | 43 (18) | 134 (64) | 303 (66) | 793 (68) |
| Total | 1932 | 245 | 210 | 456 | 1166 |
a
The sample type and sequencing platform data are specific to the sample inquired about in the survey.
b
If a patient had multiple samples sequenced, the highest OncoKB level is recorded here.